Speciality: Oncology
Description:
In this insightful presentation, renowned oncologist Dr. Nagender Sharma delves into the evolving landscape of advanced urothelial carcinoma treatment. With a focus on evidence-based strategies, Dr. Sharma welcomes viewers to explore the latest advancements, clinical trial insights, and personalized approaches that are reshaping patient care. He emphasizes the importance of integrating immunotherapy, targeted therapies, and chemotherapy while addressing challenges like resistance mechanisms and biomarker-driven decision-making. This video serves as a comprehensive guide for clinicians seeking to optimize outcomes in this complex malignancy.
Dr. Sharma meticulously examines cutting-edge therapies such as immune checkpoint inhibitors, antibody-drug conjugates (e.g., enfortumab vedotin), and FGFR inhibitors, highlighting their roles in first-line and subsequent treatments. He discusses real-world applications of combination regimens, patient selection criteria, and the impact of molecular profiling on tailoring therapies. Additionally, he sheds light on emerging trends, including adaptive clinical trial designs and the potential of novel biomarkers to refine prognostic accuracy. His analysis balances optimism with pragmatism, acknowledging hurdles like toxicity management and access disparities.
Concluding with a forward-looking perspective, Dr. Nagender Sharma underscores the collaborative effort required to translate scientific breakthroughs into tangible survival benefits for patients. Viewers are encouraged to watch the full video to gain actionable insights and stay abreast of this rapidly advancing field. Don’t miss this opportunity to learn from a leading expert. Subscribe for future updates and deepen your understanding of oncology’s most pressing challenges.
See More Webinars @ Hidoc Webinars
1.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
4.
Year in Review: Non-Small Cell Lung Cancer
5.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
3.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
The Importance of Having a Quick and Effective Heparin Antidote
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation